Cipla

GoApptiv provides comprehensive go-to-market solutions for pharmaceutical companies in India, focusing on enhancing healthcare access in extra-urban and rural areas. The company has developed a suite of healthcare software that includes a digital payment and promotional platform, a doctor-patient engagement platform, and a data analytics platform. By leveraging proprietary data analytics tools and a network of distribution partners, GoApptiv aims to facilitate agile market access and optimize patient experiences. This approach supports organizational growth and empowers stakeholders within the healthcare ecosystem, ensuring a cost-effective and efficient entry into the market.

ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteins to be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent.

GoApptiv provides comprehensive go-to-market solutions for pharmaceutical companies in India, focusing on enhancing healthcare access in extra-urban and rural areas. The company has developed a suite of healthcare software that includes a digital payment and promotional platform, a doctor-patient engagement platform, and a data analytics platform. By leveraging proprietary data analytics tools and a network of distribution partners, GoApptiv aims to facilitate agile market access and optimize patient experiences. This approach supports organizational growth and empowers stakeholders within the healthcare ecosystem, ensuring a cost-effective and efficient entry into the market.

GoApptiv provides comprehensive go-to-market solutions for pharmaceutical companies in India, focusing on enhancing healthcare access in extra-urban and rural areas. The company has developed a suite of healthcare software that includes a digital payment and promotional platform, a doctor-patient engagement platform, and a data analytics platform. By leveraging proprietary data analytics tools and a network of distribution partners, GoApptiv aims to facilitate agile market access and optimize patient experiences. This approach supports organizational growth and empowers stakeholders within the healthcare ecosystem, ensuring a cost-effective and efficient entry into the market.

GoApptiv provides comprehensive go-to-market solutions for pharmaceutical companies in India, focusing on enhancing healthcare access in extra-urban and rural areas. The company has developed a suite of healthcare software that includes a digital payment and promotional platform, a doctor-patient engagement platform, and a data analytics platform. By leveraging proprietary data analytics tools and a network of distribution partners, GoApptiv aims to facilitate agile market access and optimize patient experiences. This approach supports organizational growth and empowers stakeholders within the healthcare ecosystem, ensuring a cost-effective and efficient entry into the market.

Wellthy Therapeutics is focused on advancing health equity through digital care solutions globally. The company addresses significant challenges such as disparities in access to healthcare, poor patient outcomes, and socio-economic barriers. By offering patient-companion and concierge services that utilize behavioral science, Wellthy aims to deliver measurable clinical and business outcomes. Their platform enables partners to develop and maintain next-generation digital solutions through a unified, clinically validated front-end, supported by a regulatory-compliant back-end. This approach empowers organizations to create effective digital care services that enhance patient engagement and improve overall health outcomes.

GoApptiv provides comprehensive go-to-market solutions for pharmaceutical companies in India, focusing on enhancing healthcare access in extra-urban and rural areas. The company has developed a suite of healthcare software that includes a digital payment and promotional platform, a doctor-patient engagement platform, and a data analytics platform. By leveraging proprietary data analytics tools and a network of distribution partners, GoApptiv aims to facilitate agile market access and optimize patient experiences. This approach supports organizational growth and empowers stakeholders within the healthcare ecosystem, ensuring a cost-effective and efficient entry into the market.

Exelan Pharmaceuticals is a privately held sales and marketing company, with a focus on generic pharmaceuticals for the government and institutional market. We are allied with a low cost world leader in pharmaceutical API’s and Intermediates. Exelan will offer a wide range of therapeutic products to the marketplace.

Quality Chemicals Limited imports and distributes human health, animal health, and environmental and public health products in Uganda.

Chase Pharmaceuticals (CPC) is engaged in the identification and clinical development of medically improved, commercially promising, treatments for central nervous system (CNS) disease. The Company was incorporated in 2007 to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those with neuropsychiatric disease. Operations thus focus on selecting product candidates to license-in, adding value by advancing towards global registration, and licensing-out to commercial partners. There success reflects an exceptional ability to select promising drug candidates, intimate knowledge of the development process as well as our ability to devise the most efficient path to regulatory approval. Since inception, CPC has sought to develop novel compounds that could improve the treatment of AD and related neurodegenerative disorders. Alzheimer’s disease constitutes the largest unmet medical need in neuropsychiatry. No emerging therapies have clearly demonstrated the potential to fulfill this medical need. Symptoms include an increasing loss of memory and other cognitive functions later combined with a variety of neuropsychiatric and behavioral disturbances. Progression is relentless, typically leading to death within 10 to 15 years. AD is now recognized as the third leading killer in the U.S. It is estimated that the 37 million afflicted worldwide cost society over $600 billion annually. As the population ages, this burden will rapidly climb to unsustainable levels. Although US sales of Alzheimer’s disease medications last year topped $4.7 billion, none of the current treatments improve symptoms more than marginally. Moreover, tolerability is poor, dose titration prolonged, and dropout rates high. Chase founders have invented and patented a unique combination of proven, currently marketed pharmaceuticals that we believe will benefit the symptomatic treatment of AD.

Meditab Specialities Pvt. Ltd. engages in manufacturing and packing of pharmaceutical products such as tablets.